Evaluation of a Standardized Treatment Regimen of Anti-Tuberculosis Drugs for Patients with MDR-TB (ST REAM) Nehemiah Nhando UZ-UCSF ANNUAL RESEARCH DAY.

Slides:



Advertisements
Similar presentations
The TB Alliance-Bayer Moxifloxacin Deal
Advertisements

ISTC Training Modules 2008 Your name Institution/organization Meeting Date.
New approaches in TB diagnosis and treatment Prof. M.A. Tageldin.
Overview of current case and treatment outcome definitions Malgosia Grzemska TB Operations and Coordination Stop TB Department Consultation Impact of WHO-endorsed.
World Health Organization TB Case Definitions
New drugs and regimens for TB: 2015 update
Group II Treatment regimens, hospitalization. DOT provision, outcome definitions, management of adverse drug reactions.
1 Identifying Cases of MDR-TB Session 3. USAID TB CARE II PROJECT Old WHO recommendations RegimenIndications 4HREZ/2HR (Category I) New cases 2SHREZ/1HREZ/5HRE.
Development of extensive drug resistance in Multi-Drug resistant tuberculosis patients MSF anti-TB programmes in Abkhazia and Uzbekistan Authors: Cathy.
Efficacy and Safety of a 4-Drug Fixed- Dose Combination Regimen Compared With Separate Drugs for Treatment of Pulmonary Tuberculosis The Study C Randomized.
TB new treatments and new methodological challenges Dr Corinne Merle.
XDR-TB and management options Ninth Technical Advisory Group and National TB Programme Managers Meeting TB Control in the Western Pacific Region, Manila,
National Institute for Infectious Diseases L. Spallanzani Roma, Italy Constrains and common mistakes in TB/MDR TB clinical trials Delia Goletti and Giovanni.
Interim analysis of a double- blind, placebo-controlled study with TMC207 in patients with Multi-Drug Resistant (MDR) Tuberculosis Karel de Beule, CDTL.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2011.
TB. Areas of Concern TB cases continue to be reported in every state Drug-resistant cases reported in almost every state Estimated million persons.
Tuberculosis in the UK 2013 report
Overview of current MDR-TB case definitions and treatment outcome Dennis Falzon Consultation : Impact of WHO-endorsed molecular diagnostics on TB and MDR-TB.
4 th National Anti-tuberculosis Drug Resistance Survey Botswana, 2007.
The Global Plan to Stop TB, (1)
The global TB situation (1)
MDR-TB: a fight we cannot afford to lose! Alexander Golubkov, MD, MPH Senior TB Technical Advisor.
Operational Research in the 21 st Century. International Union Against Tuberculosis and Lung Disease (The Union) World’s oldest humanitarian organization.
Multi-drug resistant tuberculosis: Progress and challenges in South Africa Dr S. Moyo HIV/AIDS, Sexually Transmitted Infections and TB research (HAST)Programme.
Outcomes among patients treated for tuberculosis in Limpopo Province, South Africa, Mmakgotso Pilane, Lazarus Kuonza, Eric Maimela.
Tuberculosis Research of INA-RESPOND on Drug-resistant
Ongoing trials with new drugs/regimens: the fluoroquinolone case J. Grosset, E. Nuermberger & R.Chaisson Center for TB Research, Johns Hopkins University.
TB 101 Part II Brenda Mayes, R. N. March TREATMENT TB DISEASE MDR XDR LATENT TB INFECTION.
Progress of the Singapore TB Elimination Programme (STEP)
What is a non-inferiority trial, and what particular challenges do such trials present? Andrew Nunn MRC Clinical Trials Unit 20th February 2012.
Washington D.C., USA, July 2012www.aids2012.org Implementing Xpert ® MTB/RIF in Rural Zimbabwe Impact on diagnosis of smear-negative TB and time-
Unit 11 Drug Resistance and MDR-TB: B Family Case Botswana National Tuberculosis Programme Manual Training for Medical Officers.
1 EFFICACY OF SHORT COURSE AMOXICILLIN FOR NON-SEVERE PNEUMONIA IN CHILDREN (Hazir T*, Latif E*, Qazi S** AND MASCOT Study Group) *Children’s Hospital,
By: Mpho Kontle and Topo Moses. Introduction & Etiology Multi-drug-resistant tuberculosis (MDR-TB) is defined as tuberculosis that is resistant to at.
STREAM & TRUNCATE trials Andrew Nunn MRC Clinical Trials Unit at UCL Institute of Clinical Trials and Methodology University College, London, UK.
OUTCOME OF STAVUDINE INDUCED PERIPHERAL NEUROPATHY IN HIV-1 POSITIVE PATIENTS SWITCHED OR SUBSTITUTED TO A NON-STAVUDINE- BASED REGIMEN Dr P Gorejena-Chidawanyika.
Hot Topics in Infectious Diseases Giuseppe Nunnari.
Tuberculosis in Children: Treatment and Monitoring Module 10B - March 2010.
Novel Regimen Options for DR-TB Treatment
Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis UZ-UCSF ARD April 08, 2016 W.Samaneka MBChB, MSc Clin Epi, Dip HIV Man.
E FFICACY AND S AFETY OF A 4-D RUG F IXED -D OSE C OMBINATION R EGIMEN C OMPARED W ITH S EPARATE D RUGS FOR T REATMENT OF P ULMONARY T UBERCULOSIS T HE.
World Tuberculosis Day 2016 Monitoring the implementation of the Framework Action Plan to Fight Tuberculosis in the European Union – Situation in 2014.
#AIDS2016 Innovations in TB treatment : what the future holds C. Padmapriyadarsini National Institute for Research in Tuberculosis Indian.
Comprehensive Treatment of Extensively Drug-Resistant Tuberculosis N Engl J Med 2008;359: R2 이 설 라.
Taipei, June Content  Introduction about Vietnam’s Programmatic Management of Drug resistant Tuberculosis (PMDT) and drug resistant tuberculosis.
IMPAACT 2001 STUDY Mhembere T.P. (B. Pharm (Hons), MPH)
Treatment for Multi-drug Resistant TB
STREAM Trials Andrew Nunn MRC Clinical Trials Unit at UCL
The story of Munya* (and us)
A Way out of Directly Observed Therapy (DOT): Community approaches to Self-Administered Treatment for Rifampicin Resistant Tuberculosis in Khayelitsha,
STAND Trial NC-006 (M-Pa-Z) Dr Suzanne Staples Principal Investigator at THINK 26 Mar 2015.
Treatment of TB Disease
On behalf of The MTN-020/ASPIRE Study Team
Alcohol, Other Drugs, and Health: Current Evidence
Tolerability of Isoniazid Preventive Therapy (IPT) in an HIV infected cohort
2. Active TB drug-safety monitoring : rationale and mechanisms in the context of TB & MDR-TB treatment Multi-partner training package on active TB drug.
MDR-TB Update Dr Kelvin Charambira
Safe and effective bedaquiline treatment of drug-resistant tuberculosis (DR-TB) within the National Bedaquiline Clinical Access Programme in South Africa.
The results are in: now what?
STREAM (Evaluation of a Standardised Treatment Regimen of Anti-tuberculosis Drugs for Patients with Multidrug-resistant Tuberculosis) treatment regimens.
World Tuberculosis Day 2016
Session 4: Expanded indications for bedaquiline and delamanid
Impact of Using Fixed Dose Combinations (FDCs) versus
Impact of Using Fixed Dose Combinations (FDCs) versus
A5338 P. G . MARIMBE-NYATSAMBO ANNUAL RESEARCH DAY 8 APRIL 2016.
24 July 2018 Treatment outcomes with bedaquiline use when substituted for second-line injectables in multidrug resistant tuberculosis: a retrospective.
Issues in TB Drug Development: A Regulatory Perspective
Improving the Use of Medications to Treat Complex Health Problems in Resource-Poor Settings: Community-Based Examples from Haiti and Peru Jennifer Furin,
MDR-TB Clinical Trials Landscape Overview: Current and Future Trials
DSD and TB/HIV services in Zimbabwe
Presentation transcript:

Evaluation of a Standardized Treatment Regimen of Anti-Tuberculosis Drugs for Patients with MDR-TB (ST REAM) Nehemiah Nhando UZ-UCSF ANNUAL RESEARCH DAY 08 April 2016 Harare

2

3

DR-TB case detection in Zimbabwe 2010 – DR - TB cases initiated on treatment 381 (92%) DR-TB cases detected 412 (43%) Estimated DR-TB cases 950

DR-TB case detection in Zimbabwe

Why New drugs/ regimens for MDR TB? 6 Current WHO recommended standard of treatment for MDR TB lasts for two years or more - Shorten therapy Isoniazid and pyrazinamide remain are toxic - Decrease toxicity Multidrug-resistant TB, or intolerance to first-line drugs - Improve efficacy

Previous Studies Successful results from MDR-TB patients treated with a 9- month regimen in Bangladesh suggest there are better options even without the introduction of new drugs The most effective regimen required a minimum of 9 months of treatment with gatifloxacin, clofazimine, ethambutol, and pyrazinamide throughout the treatment period supplemented by prothionamide, kanamycin, and high-dose isoniazid during an intensive phase of a minimum of 4 months, giving a relapse-free cure of 87.9% (95% confidence interval, ) among 206 patients. Major adverse drug reactions were infrequent and manageable – Van Deun A, Maug AKJ, Salim MAH, Das PK, Sarker MR, Daru P, et al. Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant Tuberculosis. Am J Respir Crit Care Med. 2010; 182(5):

The 9-month Bangladesh Regimen WeeksDrug doses by weight group Drug 50 kg Kanamycin* mg per kilogramme body weight Isoniazid (H) mg 400 mg 600 mg Prothionamide mg 500 mg 750 mg Clofazimine mg 100 mg 100 mg Moxifloxacin mg 600 mg 800 mg Ethambutol mg 800 mg 1200 mg Pyrazinamide mg 1500 mg 2000 mg Kanamycin 3 times/week after week 12 The intensive phase may be extended by 4 or 8 weeks if smear conversion has not occurred by 16 or 20 weeks 8

Results of the 9-month regimen in Bangladesh Introdion ObjectifMéthodes Conclusion Published cohort (206 pts) Cure82.5% Completion 5.3% Default 5.8% Death 5.3% Failure 0.5% Relapse 0.5% Overall success rate: 87.9% (95% CI 82.7, 92.6) Am J Respir Crit Care Med Vol –692, 2010

STREAM International, multi-centre, parallel-group, open-label, randomised, controlled trial …… …….. To evaluate a Standardized Treatment Regimen of Anti- Tuberculosis Drugs for Patients with MDR-TB (STREAM)……. ………. Including patients with rifampicin resistant and isoniazid-sensitive TB. 10

Why a randomised controlled trial? To eliminate risk that patient selection biased results obtained from cohort studies To assess the 9-month regimen in a variety of settings including high levels of HIV-coinfection To develop a better evidence base for shorter MDR- TB treatment If successful, to provide a new standard of care for comparison with potentially better regimens 11

STREAM Stage 1 Primary Objectives 1. To assess whether the proportion of patients with a favourable efficacy outcome at Week 132 on Regimen B is not inferior to that on Regimen A (WHO approved MDR-TB regimen) 2. To compare the proportion of patients who experience grade 3 or greater adverse events, during treatment or follow- up, on Regimen B as compared to Regimen A. 12

STREAM Stage 1 study design STREAM is a randomised controlled trial of non-inferiority design currently being conducted in Ethiopia, South Africa, Vietnam and Mongolia The control regimen (A) is the locally used WHO recommended regimen in the participating countries The study regimen (B) is closely similar to the regimen used in Bangladesh with the exception that high dose moxifloxacin replaces high dose gatifloxacin 13

Stage 1 trial entry, randomisation, treatment and follow-up 14

15 Study Population Adults (18 years or older) who has given consent for treatment and follow-up Smear-positive pulmonary tuberculosis, or if HIV positive may be smear negative Evidence of initial resistance to rifampicin on line-probe assay, GeneXpert or other DST No evidence of initial resistance to fluoroquinolone or 2 nd -line injectables on line-probe assay No pre-existent QT prolongation >500msec If pre-menopausal woman, not pregnant or breast feeding and agrees to use effective barrier contraception/IUCD during treatment

OUTCOME MEASURES FOR STAGE 1 Primary Outcome Measures The primary efficacy outcome measure comparison is the proportion of patients with a favourable outcome at Week 132 The primary safety outcome measure is the proportion of patients experiencing a grade 3 or greater adverse event, as defined by the DAIDS criteria, during treatment and follow-up. Favourable Outcome defined as negative last two culture results taken on separate visits; the latest of which being no more than six weeks earlier than Week 132 Secondary outcome measures  Time to sputum smear conversion  Time to sputum culture conversion  Time to unfavourable efficacy outcome  Time to cessation of clinical symptoms based on PI assessment  All-cause mortality during treatment or follow-up  Change of regimen for adverse drug reactions  Number of serious adverse reactions occurring on treatment and during the follow-up period  Adherence to treatment. In selected sites, costs and acceptability of Regimens A and B to stakeholders will be analysed in terms of:  Costs to the health system  Household costs  Patient treatment and support experiences  Health worker experiences 16.

Stage 1: current status Enrolment to Stage 1 commenced: July 2012 Sites: Ethiopia (2), South Africa (3), Vietnam and Mongolia 424 of initial target of 400 patients enrolled Accrual closed: June 30th 2015 Primary endpoint at 30 months Last Patient Last Visit: Q Results from Stage 1 expected: Q1/

Trial recruitment Stages 18

STREAM Stage 2 … After the provisional licensing of bedaquiline consideration was made to determine: – Possibility of including additional regimens to the STREAM trial in its present form? – if so, what would be the appropriate regimen(s) to evaluate? After extensive discussions between the study partners and other experts it was agreed that the primary interest to patients and programmes would be: – a fully oral regimen (no kanamycin) and/or – a shorter and simpler regimen – To assess the shorter regimens in a variety of settings including sites with high levels of HIV-coinfection. 19

STREAM Stage 2 design Because it is possible that Regimen B might not be found to be non- inferior to Regimen A it was decided to continue to enrol patients to Regimen A Secondary objectives include the comparisons of Regimen C and Regimen D to Regimen A; these will be particularly important if Regimen B is found to be inferior to Regimen A A total of at least 1155 participants from sites in a number of countries will be randomised to either Regimen A, Regimen B, Regimen C, or Regimen D in a ratio 1:2:2:2 (i.e. 165 allocated to Regimen A, 330 allocated to Regimen B, 330 allocated to Regimen C, and 330 allocated to Regimen D). Sample size for Stage 2 =

STREAM STAGE 2 OBJECTIVES Primary objectives: To assess whether the proportion of patients with a favourable efficacy outcome on Regimen C, the fully oral regimen, is as effective as Regimen B at 76 weeks (18 months) To assess whether the proportion of patients with a favourable efficacy outcome on Regimen D, the 6-month regimen, is as effective as Regimen B at 76 weeks (18 months) 21

Stage 2 trial entry, randomisation, treatment and follow-up 22 All Stage 2 Sites Regimen A Regimen B – 330 Regimen C – 330 Regimen D – 330 Total participants 1155 Zimbabwe Sites 100 participants

Regimens for Stage 2

OUTCOME MEASURES STAGE 2 Primary Outcome Measures The primary efficacy outcome measure of the Stage 2 comparisons is the proportion of patients with a favourable outcome at Week 76. Favourable outcome defined as negative last two culture results taken on separate visits; the latest of which being no more than six weeks earlier than Week 76. Secondary Outcome Measures  Time to sputum culture conversion  Time to sputum smear conversion  Efficacy status at end of follow-up  Time to unfavourable efficacy outcome  Time to cessation of clinical symptoms based on PI assessment All-cause mortality during treatment or follow-up  Proportion of patients experiencing a grade 3 or greater adverse event, as defined by the DAIDS criteria, during treatment and follow-up  Change of regimen for adverse drug reactions  Number of adverse events occurring on treatment and during the follow-up period  Pharmacokinetic outcomes  Adherence to treatment. In selected sites, costs and acceptability of the four regimens to stakeholders will be analysed in terms of:  Costs to the health system  Household costs  Patient treatment and support experiences  Health worker experiences. 24

STREAM STAGE 2 TRIAL TIMELINES in ZIMBABWE Partnership between The MoHCC, City of Harare, the Union MRC Clinical Trials Unit (UCL)and UZ-UCSF Research Program and Institute of Tropical Medicine Antwerp 2 sites have been assessed by the Union in late January BRIDH Harare - Khami Road Clinic in Bulawayo Applications for ethical and clinical trial regulatory authorities will start mid-March Approvals by July 2016 Training and implementation by August 2016 (start with Harare then activate Bulawayo site after 6 months) 25

Acknowledgements 26 Funder: USAID Design, Management, Analysis Impact Assessment: Liverpool School of Tropical Medicine Microbiology: Institute of Tropical Medicine, Antwerp Sponsor: The Union UZ-UCSF Collaborative Research Programme